基石金融(08112.HK):終止股份配售事項
格隆匯5月14日丨基石金融(08112.HK)公佈,內容有關公司與潮商證券有限公司就根據一般授權配售最多1144.8萬股將予發行的公司新股份訂立日期為2021年4月30日的配售協議。
由於配售協議所載完成配售事項的若干先決條件於2021年5月14日(即配售協議日期後第14天當日)或之前尚未達成,配售協議已於2021年5月14日失效,配售事項將不會進行。根據配售協議,公司於配售事項下之責任及負債將吿失效,及公司根據配售事項之所有權利及責任將予以解除(惟(i)公司支付所有因該終止已產生或將產生的費用及開支;及(ii)任何先前的違反行為除外)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.